AbCellera Biologics Inc.

ABCL

CA00288U1066

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 03:49:28 2024-04-25 pm EDT			5-day change	1st Jan Change
3.64 ^USD	-6.67%		-7.16%	-36.43%

Mar. 11	AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases	MT
Mar. 11	AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions	CI

AbCellera Biologics Inc.(NasdaqGS:ABCL) added to S&P Global BMI Index

June 21, 2021 at 12:00 am EDT

Latest news about AbCellera Biologics Inc.

AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases	Mar. 11	MT
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions	Mar. 11	CI
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024	Mar. 05	CI
AbCellera Biologics Inc. Announces Board Changes	Feb. 23	CI
Benchmark Upgrades AbCellera Biologics to Buy From Hold, Price Target is $9	Feb. 22	MT
Stifel Lowers Price Target on AbCellera Biologics to $17 From $21, Maintains Buy Rating	Feb. 21	MT
Transcript : AbCellera Biologics Inc., 2023 Earnings Call, Feb 20, 2024	Feb. 20
AbCellera Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20	CI
Earnings Flash (ABCL) ABCELLERA BIOLOGICS Reports Fiscal 2023 Revenue $38M	Feb. 20	MT
Transcript : AbCellera Biologics Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 02:15 PM	Jan. 10
KeyBanc Initiates AbCellera Biologics at Overweight With $6 Price Target, Cites 'Robust' Platform, 'Attractive' Valuation	Dec. 05	MT
Abcellera Biologics, Inc. Announces Reorganization	Nov. 28	CI
AbCellera Biologics, Inc. Announces Reduction in Workforce	Nov. 28	CI
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023	Nov. 03	CI
Transcript : AbCellera Biologics Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Earnings Flash (ABCL) ABCELLERA BIOLOGICS Posts Q3 Revenue $6.6M, vs. Street Est of $11.5M	Nov. 02	MT
AbCellera Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Piper Sandler Assumes AbCellera Biologics at Overweight With $20 Price Target	23-10-13	MT
AbCellera Expands Antibody Discovery Collaboration With Regeneron	23-09-20	MT
AbCellera Biologics Inc. Expands Multi-Target Antibody Discovery Collaboration with Regeneron	23-09-20	CI
AbCellera Biologics Shares Rise After COO Stock Purchases Disclosed	23-09-15	MT
AbCellera and Incyte to Collaborate on Therapeutic Antibody Development in Oncology	23-09-13	MT
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology	23-09-13	CI
Benchmark Adjusts AbCellera Biologics' Price Target to $12 From $20, Keeps Buy Rating	23-08-31	MT
Goldman Sachs Adjusts AbCellera Biologics' Price Target to $24 From $27, Keeps Buy Rating	23-08-04	MT

Chart AbCellera Biologics Inc.

Duration

Period

More charts

AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for AbCellera Biologics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.9 USD

Average target price

14.75 USD

Spread / Average Target

+278.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ABCELLERA BIOLOGICS INC.	-36.43%	1.14B
IQVIA HOLDINGS INC.	+1.19%	43.84B
MODERNA, INC.	+6.57%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+7.56%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.69%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.62%	12.29B
MEDPACE HOLDINGS, INC.	+27.76%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.42%	11.15B

Other Biotechnology & Medical Research